stars 1 stars 2 stars 3

enGene (Nasdaq: ENGN) is a clinical-stage biotechnology company mainstreaming non-viral genetic medicines that can be delivered locally to the site of disease—starting with non-muscle invasive bladder cancer (NMIBC) and expanding beyond. Founded in Canada, with a United States headquarters located in Boston, we are developing innovative solutions with the goal of reducing treatment burden and improving patient outcomes. To learn more about enGene visit our website: enGene.com. We are currently enrolling select patients with NMIBC in our LEGEND clinical trial. We have sites in the United States, Canada, Europe and the Asia-Pacific region. For more information, please visit TheLegendStudy.com.

enGene Questions

The enGene annual revenue was $44.8 million in 2026.

Ryan Daws is the CFO of enGene.

82 people are employed at enGene.

enGene is based in Boston, Massachusetts.

The NAICS codes for enGene are [54199, 5419, 541, 541990, 54].

The SIC codes for enGene are [73, 738].

Top enGene Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users